ESSA Pharma Inc. (EPIX)

ESSA Pharma Income Statement

Financials in millions USD. Fiscal year is October - September.

Year Ending	TTM	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019
Selling, General & Admin	11.1	10.81	12.54	12.88	11.37	5.46
Research & Development	23.05	21.32	24.42	24.26	12.15	6.7
Operating Expenses	34.15	32.13	36.96	37.14	23.52	12.15
Operating Income	-34.15	-32.13	-36.96	-37.14	-23.52	-12.15
Interest Expense / Income	0	0.01	0.01	0.02	0.62	0.6
Other Expense / Income	-6.42	-5.56	-1.76	-0.33	-0.4	-0.04
Pretax Income	-27.73	-26.58	-35.22	-36.84	-23.73	-12.72
Income Tax	0	0	-0.11	-0.03	-0.29	0.04
Net Income	-27.73	-26.58	-35.1	-36.81	-23.45	-12.76
Shares Outstanding (Basic)	44	44	44	38	22	8
Shares Outstanding (Diluted)	44	44	44	38	22	8
Shares Change	0.33%	0.12%	14.44%	71.45%	166.13%	84.68%
EPS (Basic)	-0.63	-0.60	-0.80	-0.96	-1.04	-1.51
EPS (Diluted)	-0.63	-0.60	-0.80	-0.96	-1.04	-1.51
Free Cash Flow	-21.42	-19.78	-28	-25.42	-16.98	-12.25
Free Cash Flow Per Share	-0.48	-0.45	-0.64	-0.66	-0.76	-1.45
EBITDA	-27.63	-26.46	-35.08	-36.71	-23.01	-12.12
Depreciation & Amortization	0.1	0.12	0.12	0.11	0.11	0
EBIT	-27.73	-26.57	-35.2	-36.82	-23.12	-12.12

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).